Spots Global Cancer Trial Database for A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Official Title: A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Study ID: NCT01743950
Conditions
Study Description
Brief Summary: To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27 fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until time of progression in patients with recurrent high grade gliomas (grade III and grade IV). Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior exposure to bevacizumab.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Contact Details
Name: Steve Howard, MD
Affiliation: University of Wisconsin, Madison
Role: PRINCIPAL_INVESTIGATOR
Name: H. Ian Robins, MD, Ph.D
Affiliation: University of Wisconsin, Madison
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
